ArticleJournal of gastrointestinal cancer2025
Prognostic Value of CRP-Albumin-Lymphocyte (CALLY) Index in Colorectal Cancer Survival: A Multicenter Retrospective Cohort Study.
Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic Value of Pretreatment C-Reactive-Protein-Albumin-Lymphocyte Index in Colorectal Cancer: Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Clinical significance of the pretreatment C-reactive protein-albumin-lymphocyte (CALLY) index in colorectal cancer patients: a meta-analysis.BMC cancer · 2026Pooled it
- Deciphering the potential of the C-reactive protein-albumin-lymphocyte index as a prognostic biomarker in malignancy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Preoperative Immunonutritional Indices in Colorectal Cancer: The Contribution of Albumin, Time-Dependence of Effect, and Threshold Transportability in a Saudi Cohort.Current oncology (Toronto, Ont.) · 2026Article
- Is the CALLY Index the Best Tool for Predicting Survival in Patients with Primary Soft Tissue Sarcomas?Diagnostics (Basel, Switzerland) · 2026Article
- The CALLY index as a predictive biomarker for the prognosis and treatment outcomes of colorectal cancer.Surgery today · 2026Article
- The CALLY Index Is Associated with Overall Survival in Patients with De Novo Metastatic Gastric Adenocarcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- Long-term postdischarge immunonutrition management in elective colorectal cancer surgery patients an interim analysis of a Chinese multicenter randomised controlled trial.Metabolism open · 2026Article
- Prognostic Value of Albumin-to-CEA Ratio in Metastatic Colorectal Cancer: A Retrospective Study.Biomedicines · 2026Article
- A clinical study of the CALLY index and HALP score for evaluating response to FOLFOX in colorectal cancer with lung metastases.American journal of translational research · 2026Article
- Immunologically-based nutritional status assessment amongst preoperative colorectal cancer patients - does it link to TNM stage.Frontiers in immunology · 2026Article
- Preoperative Prognostic Nutritional Index Predicts Postoperative Outcomes in Colorectal Cancer: A Propensity Score-Matched Cohort Study.Cancer management and research · 2026Article
- Multidimensional impact of venous thromboembolism on survival outcomes in ovarian cancer patients: deconstructing competing risks between thrombosis-related and tumor-related mortality.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) has become one of the major health burdens in the world with high mortality rates, especially at the advanced stages. The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is a novel multidimensional biomarker combining systemic inflammation, nutritional status, and immune function. This study evaluated the association between the CALLY index and overall survival (OS) as well as recurrence-free survival (RFS) in colorectal cancer (CRC) patients.
methodsIn this retrospective, multicenter cohort study, the medical characteristics of 1447 CRC patients who were treated at one of the medical centers affiliated with two universities of medical sciences between 2012 and 2022 were examined. Patients were divided into two groups based on the CALLY index: ≥ 2 (945 patients) and < 2 (502 patients). Demographic characteristics, tumor characteristics, and pathological findings of the patients were extracted by referring to the patient records.
resultsThe 5-year OS rate for patients with a CALLY index ≥ 2 was 80.3%, compared to 64.9% for those with a CALLY index < 2 (log-rank test = 68.2, P = 0.001). The multivariate analysis showed that the CALLY index was significantly associated with OS rate of patients, and OS rate was significantly higher in patients with a CALLY index ≥ 2 than in patients with a CALLY index < 2 (HR 0.84, 95% CI 0.73-0.95, P = 0.001). Also, based on these results, the patients' age, mean BMI, tumor size, T stage, TNM stage, presence of metastasis, tumor location, number of involved lymph nodes, colon diseases, adjuvant chemotherapy, platelet level, and pathological tumor differentiation were all significantly associated with survival in CRC patients (P < 0.05).
conclusionOur study demonstrated that a higher CALLY index is significantly correlated with improved survival outcomes and a reduced risk of recurrence in CRC patients. CALLY index can be helpful as a criterion for predicting the prognosis of patients with CRC.
Indexed as
Identifiers
40913216What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.